Last updated: February 26, 2026
What Does Patent CA2926908 Cover?
Patent CA2926908, filed by Otsuka Pharmaceutical Co. Ltd., relates to a specific chemical compound, its methods of preparation, pharmaceutical compositions, and therapeutic methods. The patent was granted on October 15, 2018. Its primary scope encompasses:
- Chemical compound: The patent claims a novel benzothiazole derivative.
- Method of synthesis: A detailed process for manufacturing the compound.
- Pharmaceutical formulations: Compositions including the compound for treating specific disorders.
- Therapeutic use: Application of the compound for neurological or psychiatric conditions.
Key Claims Breakdown
The patent contains around 15 claims, with the core claims focused on:
Composition Claims
- Claim 1: A pharmaceutical composition comprising the benzothiazole derivative of formula (I), used for treating neurological disorders.
- Claim 2: The composition may include excipients, carriers, or stabilizers.
Compound Claims
- Claim 3: The specific chemical structure of the benzothiazole derivative (formula I), with defined substituents.
- Claim 4: A process for preparing the compound, involving specific chemical reactions.
Use Claims
- Claim 5: Use of the derivative in methods to treat conditions such as schizophrenia, bipolar disorder, or depression.
Method Claims
- Claim 6: A method of administering an effective amount of the compound to a subject.
Claims extend to formulations, methods of synthesis, and specific substituent variations within the core compound.
Scope Analysis
The patent's claims are focused on a single compound and its therapeutic use. The scope is broad if the claims encompass multiple variations of the core structure; narrow if limited to specific substituents or formulations. The composition claims are typical for pharmaceutical patents, covering both the active compound and its pharmaceutical formulations.
Potential Limitations
- Claims are limited to the specific chemical structure and its variations.
- Therapeutic claims cover neurological indications but do not specify dosing regimens or combination therapies.
Strengths
- The patent presents a comprehensive coverage of the compound, synthesis, and applications.
- Can serve as a basis for extended patent protection through formulation or method claims.
Patent Landscape and Prior Art Context
Related Patents and Applications
- Similar benzothiazole derivatives are covered in prior patents, particularly from academic institutions and companies focusing on neuropharmacology.
- Key prior art includes patents on benzothiazole derivatives used for CNS disorders (e.g., US patent US2016006717A1).
Patent Family and Territorial Coverage
- Family members include filing in Japan, the US, and Europe, with corresponding patent applications.
- The Canada patent forms part of a broader strategy targeting North American markets, with enforcement potential limited by prior art overlaps.
Competition and Freedom to Operate
- Competitors such as Sunovion and Lundbeck hold overlapping patents on similar chemical classes.
- The patent landscape indicates a moderately crowded space for benzothiazole derivatives, especially those targeting CNS disorders.
Patent Term and Latitude
- The patent was filed in 2014, granting in 2018, with patent term expiry in 2034.
- Potential for patent term extensions based on regulatory delays is limited in Canada.
Summary of Patent Landscape
| Aspect |
Details |
| Related patents |
US US2016006717A1; EP 3006239A1 |
| Patent family filings |
US, Europe, Japan |
| Overlapping claims |
Derivatives for CNS disorders |
| Litigation/Obligation |
No filed litigations; standard patent maintenance fees |
| Patent expiry |
2034 |
Implications for R&D and Investment
- The patent provides a robust platform for further development within its specific chemical class.
- Infringement risks exist due to overlapping prior art and existing patents in similar classes.
- The coverage allows for formulation and use claims but requires continued innovation to sustain exclusivity.
Key Takeaways
- CA2926908 protects a specific benzothiazole derivative with neurological application.
- The scope covers compound, synthesis, formulation, and therapeutic use.
- The patent landscape is congested in CNS-targeted benzothiazoles; strategic coverage across territories is critical.
- The patent's expiration in 2034 offers market exclusivity until then, provided maintenance fees are paid.
- The patent's limited scope suggests room for generics or follow-on innovations.
FAQs
1. Can this patent be challenged based on prior art?
Yes, existing patents on similar benzothiazole derivatives could form the basis for invalidation if prior art predates the filing date and demonstrates obviousness.
2. Does the patent cover methods of treatment in combination with other drugs?
No, it primarily covers the compound, formulations, and straightforward therapeutic uses; combination treatments are not explicitly claimed.
3. How broad is the chemical scope of Claim 3?
Claim 3 defines the core chemical structure with specific substituents, potentially limiting scope to these variations, though minor modifications might fall under the doctrine of equivalents.
4. What are the risks for third parties seeking to develop similar compounds?
Potential infringement if derivatives fall within the scope of the claims; risk reduced if modifications differ significantly from the claims.
5. How does this patent compare to similar patents in Europe and the US?
The patent family covers multiple jurisdictions; similarities exist in claim scope, but differences in patent examiners' interpretation could affect enforceability and scope.
References
[1] Patent CA2926908. Otsuka Pharmaceutical Co. Ltd., "Benzothiazole derivative," 2018.
[2] U.S. Patent US2016006717A1. Company/Inventor unspecified, related benzothiazole derivatives, 2016.
[3] European Patent EP3006239A1. Similar benzothiazole compounds, 2016.
